1. Home
  2. IIPR vs ANAB Comparison

IIPR vs ANAB Comparison

Compare IIPR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

HOLD

Current Price

$57.46

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$52.33

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIPR
ANAB
Founded
2016
2005
Country
United States
United States
Employees
23
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
IIPR
ANAB
Price
$57.46
$52.33
Analyst Decision
Hold
Buy
Analyst Count
3
12
Target Price
$45.00
$71.67
AVG Volume (30 Days)
213.2K
559.1K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
14.28%
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$2.69
N/A
Revenue Next Year
$3.80
$52.14
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
157.01
52 Week Low
$44.58
$17.11
52 Week High
$61.40
$73.30

Technical Indicators

Market Signals
Indicator
IIPR
ANAB
Relative Strength Index (RSI) 56.48 34.13
Support Level $53.80 $43.75
Resistance Level $59.37 $57.70
Average True Range (ATR) 1.29 2.79
MACD -0.01 -1.04
Stochastic Oscillator 73.94 14.71

Price Performance

Historical Comparison
IIPR
ANAB

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: